Brief: Paratek Pharmaceuticals Reports Q1 2020 Total Revenues Of $7.9 Million
11/05/2020 13:18
May 11 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 TOTAL
REVENUES OF $7.9 MILLION INCLUDING NUZYRA® (OMADACYCLINE) NET
SALES OF $7.3 MILLION
* Q1 LOSS PER SHARE $0.66
* Q1 EARNINGS PER SHARE ESTIMATE $-0.80 -- REFINITIV IBES
DATA
* SEES FY 2020 REVENUE $75 MILLION TO $80 MILLION
* AS OF MARCH 31, 2020, PARATEK HAD $194.8 MILLION IN CASH,
CASH
EQUIVALENTS AND MARKETABLE SECURITIES
* CURRENTLY MAINTAINING ITS FULL YEAR 2020 FINANCIAL
GUIDANCE
Source text for Eikon: ID:nGNX3MRzRW
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million